| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.048 | 0.3 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.3 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.046 | 0.3 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.06 | 0.3 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.032 | 0.3 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |